CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Endpoints News
Original article

FDA should follow EMA's lead on drug rejection disclosures, researchers say

RegulatoryNeutral
AI Analysis

Summary

Researchers recommend the FDA follow the European Medicines Agency's approach for publishing drug rejection letters, following the FDA's September 2025 decision to begin disclosing rejections.

Importance:3/10
Sentiment:
0.00
FDAtransparencydrug rejectionsregulatory disclosureEMA

Read the original article

Published by Endpoints News on September 9, 2026 4:51 PM

Read Original